Alaunos Therapeutics, Inc.
TCRT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 89.37 | 0.32 | -0.01 | 0.03 |
| FCF Yield | -0.19% | 104.23% | -32.80% | -19.36% |
| EV / EBITDA | -4,430.65 | -5.05 | -1.90 | -2.65 |
| Quality | ||||
| ROIC | -42.35% | -28.38% | -103.21% | -36.60% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.73 | 0.67 | 0.72 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | -26.32% | -87.30% | -84.93% | -85.45% |
| Free Cash Flow Growth | -219.38% | 1,197.67% | -30.41% | -102.05% |
| Safety | ||||
| Net Debt / EBITDA | 1.63 | 2.77 | 0.30 | 1.47 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -393.57 | 90.00 | 112.50 |